Organovo (NASDAQ:ONVO) Now Covered by StockNews.com

StockNews.com began coverage on shares of Organovo (NASDAQ:ONVO) in a report issued on Sunday. The firm set a “sell” rating on the medical research company’s stock.

Organovo Stock Down 2.6 %

Shares of ONVO stock opened at $0.37 on Friday. The stock has a fifty day moving average of $0.38 and a 200 day moving average of $0.44. Organovo has a 52 week low of $0.32 and a 52 week high of $1.74. The firm has a market capitalization of $6.44 million, a price-to-earnings ratio of -0.43 and a beta of 0.54.

Organovo (NASDAQ:ONVO) last announced its quarterly earnings results on Wednesday, February 19th. The medical research company reported ($0.19) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.02. Organovo had a negative return on equity of 346.26% and a negative net margin of 10,151.64%. The company had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.05 million. Equities research analysts anticipate that Organovo will post -0.77 earnings per share for the current year.

About Organovo

Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.